Solana Company (HSDT) Q1 2025 Earnings Report

Solana Company (HSDT) delivered a materially challenging Q1 2025 with negligible revenue and a substantial operating loss. Revenue for the quarter stood at USD 49,000, versus cost of revenue of USD 121,000, producing a gross loss of USD -72,000 and a gross margin of -1.47%. Aggressive fixed and variable spend drove a total operating expense of USD 3.94 million (R&D USD 0.95 million; SG&A USD 2.99 million), culminating in EBITDA of USD -4.00 million and an operating loss of USD -4.01 million. Net income was USD -3.84 million, translating to an EPS of -$7.65 on 503,751 diluted shares. The company closed the period with USD 1.11 million in cash and equivalents, after a cash burn from operations of USD -3.54 million for the quarter. Financing activity provided USD 5.56 million, resulting in a net cash increase of USD 0.02 million and a cash balance of USD 1.11 million at period end. There is no outstanding debt reported, but negative retained earnings of USD -175.54 million dwarf the equity base (total stockholders’ equity USD 1.28 million), signaling a severely scaffolded balance sheet and persistent capital raises required to fund ongoing operations.

Given the lack of formal forward guidance in the provided data, the near-term outlook hinges on management’s ability to secure licensing deals or strategic partnerships that could monetize the platform technologies and extend the company’s cash runway. The core risk is existential liquidity without meaningful revenue traction, balanced by potential upside if a licensing or collaboration path materializes. Investors should monitor for updates to guidance, progress on clinical validation, and any coupling of product commercialization with reimbursements or payer acceptance.